Emcure Pharmaceuticals raises ₹582 crore from anchor investors in its IPO, reflecting strong investor confidence. Backed by Bain Capital, Emcure aims for continued growth in the booming pharmaceutical market.
Explore investing in high-yield dividend stocks near their 52-week lows. Learn about Pfizer, Bristol-Myers Squibb, and Gilead Sciences, prime candidates for a buy-and-hold strategy with substantial dividend yields.
